Drug delivery nanogel to transform medical devices
CM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices
Millions of patients annually come into contact with intravenous (iv) catheters and other medical devices, with an associated risk of blood clots and infection. Bloodstream infections from iv catheters can cost up to $46,000 per episode with a 15% mortality rate. In addition, thrombosis affects up to 18% of patients.
Better outcomes needed
Driven by this clear clinical need and proprietary scientific insights, the scientists and clinicians at CM4Cure have developed a breakthrough nanogel coating, CMD-COAT®. It is capable of delivering up to six active pharmaceutical ingredients (APIs) with controlled release. Focused on improved performance and safety, CMD-COAT® transforms medical device surfaces into platforms for API delivery. Hydrophilic, loadable, durable and scalable as well as compatible with plastics, metals and biological tissue, the nanogel can be used with both insertable and implantable devices. This includes iv catheters, implantable ports, heart valve implants and devices across a range of other clinical areas. Existing medical device coatings offer limited protection against blood clots and infections, contrasting with our bioactive drug delivery coatings.
Differentiate your device
When loaded with Fluometacyl® – one of our patented APIs derived from a FDA-approved drug – CMD-COAT® delivers powerful protection against both thrombosis and infection, the first coating with this dual effect.
Medical device partners may be interested in this drug-coating combination or working with us on developing their own API formulations (eg coatings to prevent restenosis or calcification/enhance healing or hemostasis are possible). The ability to tune CMD-COAT® with a partner’s APIs of choice ensures drug delivery is possible across a range of medical devices, bringing product differentiation, premium pricing and growth in market share.
Even without APIs, CMD-COAT® offers exceptional protection. Its hydrophilic surface resists fouling from microbes and proteins and the coating does not interfere with device design nor functionality. The nanogel also increases device lubrication, reducing damage to fragile tissues including blood vessel walls.
Ultra-thin layers can be deposited allowing controlled release on the internal surfaces of the smallest catheters or in complex devices, meaning easy integration of the water-based technology into existing manufacturing processes.
CM4Cure believes healthcare systems can achieve extensive savings through simultaneous prevention of infections and thrombosis associated with medical device use.
Talk to us about how you can benefit from the CMD-COAT® drug delivery system, providing a unique way to differentiate your product.
Contact:
Colm McCarthy, CEO
Colm.Mccarthy@cm4cure.com
www.cm4cure.com
This Advertorial was originally published in European Biotechnology Magazine Summer 2026.
adobe stock photos - Michael Derrer Fuchs 
Certest